FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRelmada Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RLMD
Relmada Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Relmada Therapeutics, Inc. (RLMD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRLMD
RLMD
Relmada Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RLMD
  1. Home
  2. Stocks
  3. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

🇺🇸RLMD•NASDAQ

Relmada Therapeutics, Inc.

🇺🇸RLMD•NASDAQ
Market cap
$304.61M

Your view on RLMD

Mkt Cap
$304.61M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Relmada Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Sergio Traversa
Headquarters
2222 Ponce de Leon Boulevard, Coral Gables, FL, US
Industry
Biotechnology
Sector
Healthcare
CEO
Sergio Traversa
Headquarters
2222 Ponce de Leon Boulevard, Coral Gables, FL, US
Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.

Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.

The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Relmada Therapeutics, Inc.. Starting points for Relmada Therapeutics, Inc.: EPS -$0.58, beta 0.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Relmada Therapeutics, Inc.. Trailing twelve-month EPS for Relmada Therapeutics, Inc. stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$9.75

average of 4 firms, last 12 months

 

$9.75

Low $8.00

Median $9.50

High $12.00

 

Analyst Ratings

Buy8 ratings
  • Strong Buy0
  • Buy5
  • Hold2
  • Sell1
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$0.13−$0.15−$0.56−$0.75
Low estimate−$0.16−$0.17−$0.56−$0.94
High estimate−$0.09−$0.11−$0.55−$0.55
No. of analysts3222
Year-ago EPS−$0.271−$0.22−$1.451—
Growth—+34.1%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$10.00M$32.45M
Low estimate$0.00$0.00$10.00M$32.45M
High estimate$0.00$0.00$10.00M$32.45M
No. of analysts0034
Year-ago revenue$0.00$0.00$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Jun 18, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Relmada Therapeutics, Inc.. Relmada Therapeutics, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RLMD19 companies · 8 funds
Compare RLMD with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACETAdicet Bio, Inc.HealthcareBiotechnology$23.4M
ACRVAcrivon Therapeutics, Inc. Common StockHealthcareBiotechnology$66.9M
CBUSCibus, Inc.HealthcareBiotechnology$104.7M
FBIOFortress Biotech, Inc.HealthcareBiotechnology$63.0M
IMUXImmunic, Inc.HealthcareBiotechnology$102.6M
LITSLite Strategy, Inc.HealthcareBiotechnology$24.1M
PMVPPMV Pharmaceuticals, Inc.HealthcareBiotechnology$65.1M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
VRDNViridian Therapeutics, Inc.HealthcareNASDAQ$3.4B
VRPXVirpax Pharmaceuticals, Inc.HealthcareNASDAQ$26,093
VRTXVertex Pharmaceuticals IncorporatedHealthcareNASDAQ$136.0B
VRXAVeraxa Biotech Holding AGHealthcareNASDAQ$145.7M
VRXAWVeraxa Biotech AGHealthcareNASDAQ$579,370
SPRCSciSparc Ltd.HealthcareNASDAQ$156,921
SPROSpero Therapeutics, Inc.HealthcareNASDAQ$50.9M
SPRYARS Pharmaceuticals, Inc.HealthcareNASDAQ$370.9M
SPTXSeaport Therapeutics, Inc. Common StockHealthcareNASDAQ$980.1M
SQZBSQZ Biotechnologies CompanyHealthcareOTC$707,787
SRBCFSirona Biochem Corp.HealthcareOTC$1.6M
SRNESorrento Therapeutics, Inc.HealthcareOTC$2.6M
ETFs holding Relmada Therapeutics, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.01%
XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets0.76%
BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets0.39%
SBIOALPS Medical Breakthroughs ETF$187M in assets0.23%
IWCiShares Micro-Cap ETF$1.2B in assets0.08%
VFMOVanguard U.S. Momentum Factor ETF$1.9B in assets0.05%

Largest holders first, then the funds most concentrated in RLMD.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Relmada Therapeutics, Inc., and how their positions are changing. At a $304.6M market value, institutional positions materially move Relmada Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Relmada Therapeutics, Inc. executives and directors. Shares of Relmada Therapeutics, Inc. have traded between $0.24 and $4.38 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Relmada Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Relmada Therapeutics, Inc.. Coverage tracks Relmada Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Relmada Therapeutics, Inc.

RLMD AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1

News

Latest Market News